Almirall: collaboration with Evotec; positive phase III data
(CercleFinance.com) - Spanish pharmaceutical company Almirall is having a busy day on Monday.
The Barcelona-based firm has entered into a research collaboration in the field of dermatological diseases with German biotech firm Evotec.
The companies said they plan a novel approach to disrupt cell signaling, delivering highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis.
Under the terms of the agreement, Evotec will receive research funding and may be eligible to receive milestone payments and royalties.
Almirall also said that two phase III trials have showed the efficacy and safety over three years of its tildrakizumab antibody in patients with moderate-to-severe chronic plaque psoriasis.
The data was presented at the European Academy of Dermatology and Venerology (EADV) congress in Paris on Saturday.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Barcelona-based firm has entered into a research collaboration in the field of dermatological diseases with German biotech firm Evotec.
The companies said they plan a novel approach to disrupt cell signaling, delivering highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis.
Under the terms of the agreement, Evotec will receive research funding and may be eligible to receive milestone payments and royalties.
Almirall also said that two phase III trials have showed the efficacy and safety over three years of its tildrakizumab antibody in patients with moderate-to-severe chronic plaque psoriasis.
The data was presented at the European Academy of Dermatology and Venerology (EADV) congress in Paris on Saturday.
Copyright (c) 2018 CercleFinance.com. All rights reserved.